Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa

撒哈拉以南非洲地区SARS-CoV-2感染患者的独特临床和免疫学特征

阅读:4
作者:Ben Morton # ,Kayla G Barnes # ,Catherine Anscombe ,Khuzwayo Jere ,Prisca Matambo ,Jonathan Mandolo ,Raphael Kamng'ona ,Comfort Brown ,James Nyirenda ,Tamara Phiri ,Ndaziona P Banda ,Charlotte Van Der Veer ,Kwazizira S Mndolo ,Kelvin Mponda ,Jamie Rylance ,Chimota Phiri ,Jane Mallewa ,Mulinda Nyirenda ,Grace Katha ,Paul Kambiya ,James Jafali ,Henry C Mwandumba ,Stephen B Gordon ,Kondwani C Jambo #

Abstract

Although the COVID-19 pandemic has left no country untouched there has been limited research to understand clinical and immunological responses in African populations. Here we characterise patients hospitalised with suspected (PCR-negative/IgG-positive) or confirmed (PCR-positive) COVID-19, and healthy community controls (PCR-negative/IgG-negative). PCR-positive COVID-19 participants were more likely to receive dexamethasone and a beta-lactam antibiotic, and survive to hospital discharge than PCR-negative/IgG-positive and PCR-negative/IgG-negative participants. PCR-negative/IgG-positive participants exhibited a nasal and systemic cytokine signature analogous to PCR-positive COVID-19 participants, predominated by chemokines and neutrophils and distinct from PCR-negative/IgG-negative participants. PCR-negative/IgG-positive participants had increased propensity for Staphylococcus aureus and Streptococcus pneumoniae colonisation. PCR-negative/IgG-positive individuals with high COVID-19 clinical suspicion had inflammatory profiles analogous to PCR-confirmed disease and potentially represent a target population for COVID-19 treatment strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。